Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of CBP-201 Monotherapy in Patients With Moderate-To-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rademikibart (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Suzhou Connect Biopharmaceuticals

Most Recent Events

  • 04 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 30 Dec 2022 According to a Connect Biopharma Australia media release, in light of the current macroeconomic climate and challenging funding environment, company feel that it is necessary and financially prudent to commence Global Phase 3 program for CBP-201 in moderate-to-severe AD after it has secured the partnership necessary to fully complete the program.
  • 11 Jul 2022 According to a Connect Biopharma Australia media release, the company expect to enroll first patient by the end of 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top